Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Intensifies Health Claims Scrutiny, Enforcement Strategies

This article was originally published in The Tan Sheet

Executive Summary

A joint Federal Trade Commission/FDA working group will evaluate claims made for dietary supplements, conventional foods and OTC drugs, said the commission's Consumer Protection Director David Vladeck
Advertisement

Related Content

FDA-FTC Collaboration Relies On Joint Enforcement, Not Single Agency Acts
U.K. Advertising Watchdog Will Monitor Facebook, Twitter Ads
FTC proposes fraud survey
$100 Million Acai Case Could Be Tip Of FTC's Enforcement Iceberg
FTC Prioritizes Food Advertising Investigations Over Supplement Claims
FTC Provision In Finance Reform Bill Could Bite Supplement Firms
FTC's Pending Claim Substantiation Changes Will Weigh On Small Firms
Pharma Industry Watchdog Brill Nominated For FTC Commissioner
FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims
FTC Consumer Chief Vladeck’s Reputation Precedes Him

Topics

Advertisement
UsernamePublicRestriction

Register

PS103413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel